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OBJECTIVES We sought to evaluate the influence of pretreatment systolic blood pressure (SBP) on the
efficacy and safety of carvedilol in patients with chronic heart failure (CHF).
BACKGROUND Although beta-blockers reduce the risk of death in CHF, there is little reported experience with
these drugs in patients with a low pretreatment SBP, who may respond poorly to beta-blockade.
METHODS We studied 2,289 patients with severe CHF who participated in the Carvedilol Prospective
Randomized Cumulative Survival (COPERNICUS) trial.
RESULTS Compared with placebo, carvedilol improved the clinical status and reduced the risk of death and
the combined risk of death or hospitalization for any reason, for a cardiovascular reason, or for
worsening heart failure (p  0.001 for all). The relative magnitude of these benefits did not vary
as a function of the pretreatment SBP (all interaction: p 0.10). However, because patients with
the lowest SBP were at highest risk of an event, they experienced the greatest absolute benefit from
treatment with carvedilol. The lower the pretreatment SBP, the more likely that patients would
report an adverse event, be intolerant of high doses of the study drug, or require permanent
withdrawal of treatment (p  0.001 for all). However, these risks were primarily related to the
severity of the underlying illness and not to treatment with carvedilol.
CONCLUSIONS The current study provides little support for concerns about using beta-blockers (particularly
those with vasodilatory actions) in patients with severe CHF who have a low SBP.
Pretreatment blood pressure can identify patients who have the greatest need for risk
reduction with carvedilol. (J Am Coll Cardiol 2004;43:1423–9) © 2004 by the American
College of Cardiology Foundationm
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Slthough beta-blockers have been shown to reduce the risk of
eath in patients with chronic heart failure (CHF) (1–4),
See page 1430
ome physicians hesitate to prescribe these drugs to high-risk
atients because of fears that treatment with these agents
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Manuscript received June 23, 2003; revised manuscript received October 20, 2003,cccepted November 18, 2003.ight interfere with homeostatic actions of the sympathetic
ervous system (5). Because adrenergic stimulation serves to
upport both blood pressure (BP) and cardiac contractility in
atients with impaired left ventricular function, the adminis-
ration of adrenergic blocking drugs can produce both hypo-
ension and worsening heart failure (HF) (5,6). The risk of
hese adverse circulatory reactions appears to be most marked
n patients with the lowest BP or most advanced disease before
reatment (6,7). Such patients have generally responded poorly
o treatment and have frequently been excluded from partici-
ation in clinical studies using beta-blocking drugs. For exam-
le, large-scale trials with metoprolol and bisoprolol in HF
ocused on patients with mild or moderate symptoms and did
ot enroll those with pretreatment systolic blood pressure
SBP) of 100 mm Hg (2,3).
The Carvedilol Prospective Randomized Cumulative
urvival (COPERNICUS) study evaluated the effects of
arvedilol in patients with severe CHF, including those with
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The COPERNICUS Study April 21, 2004:1423–9very low SBP (85 to 100 mm Hg). The trial demonstrated
reduction in the risk of death and of hospitalization in
hese patients (4,8), but earlier publications did not explore
hether pretreatment BP influenced the presence or
agnitude of these benefits. Such analyses would be partic-
larly relevant for the use of carvedilol, as the vasodilatory
ffects of the drug might be expected to lower blood pressure
nd thus could theoretically place patients with CHF with
he lowest BP at risk of hypotension. Such concerns,
ogether with the absence of clinical trial data, may lead
hysicians to avoid the use of carvedilol and other beta-
lockers in patients with a low SBP.
This report describes a retrospective analysis of the
nfluence of the pretreatment SBP on the efficacy and safety
f carvedilol in patients with severe CHF.
ETHODS
he protocol was approved by the institutional review
oards of all participating institutions, and written, in-
ormed consent was obtained from all patients.
tudy patients. Patients with severe CHF due to an
schemic or non-ischemic cardiomyopathy were enrolled at
34 centers in 21 countries. All patients had dyspnea or
atigue at rest or on minimal exertion for two or more
onths and a left ventricular ejection fraction 25%,
espite appropriate conventional therapy. Such therapy was
efined as treatment with diuretics (in doses adjusted to
chieve clinical euvolemia) and an angiotensin-converting
nzyme (ACE) inhibitor or angiotensin II receptor antag-
nist (unless such therapy was not tolerated). Treatment
ith digitalis, spironolactone, vasodilators, and amiodarone
as allowed but not required. Clinical euvolemia was
efined as the absence of rales and ascites and the presence
f no more than minimal peripheral edema, unless these
igns were considered to be due to non-cardiac causes.
ospitalized patients could be enrolled, but only if they had
o acute cardiac or non-cardiac illness that required contin-
ed inpatient care. Unlike earlier survival trials, the CO-
ERNICUS trial imposed no stability criteria with respect
o the use of background medications and allowed patients
n the study as long as their SBP was 85 mm Hg.
Patients were not enrolled in the study if they had a
eversible or surgically correctable cause of HF; had received
r were likely to receive a heart transplant; had severe
rimary pulmonary, renal, or hepatic disease; or had a
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BP  blood pressure
CHF  chronic heart failure
COPERNICUS  Carvedilol Prospective Randomized
Cumulative Survival trial
HF  heart failure
SBP  systolic blood pressureontraindication to beta-blocker therapy. In addition, rithin the preceding two months, patients were not allowed
o have had cardiac surgery or angioplasty, a myocardial or
erebral ischemic event, or sustained a hemodynamically
estabilizing ventricular tachyarrhythmia. Patients who had
eceived an alpha-adrenergic blocker, calcium channel
locker, or class I antiarrhythmic drug within four weeks; a
eta-adrenergic blocker within two months; or an intrave-
ous positive inotropic agent or intravenous vasodilator
ithin four days were not permitted into the study. Finally,
atients were excluded if they had a heart rate 68
eats/min, serum creatinine 2.8 mg/dl, serum potassium
3.5 or 5.2 mmol/l, or an increase in serum creatinine by
0.5 mg/dl, or a change in body weight 1.5 kg within 3
o 14 days of randomization.
tudy design. Patients who fulfilled all the entry criteria
ere randomly assigned in a 1:1 ratio and in a double-
linded fashion to receive either oral carvedilol (n  1,156)
r matching placebo (n  1,133), in addition to their usual
edications for HF. Patients received an initial dose of
.125 mg carvedilol or placebo twice daily for two weeks,
hich was then increased at two-week intervals (if toler-
ted), first to 6.25 mg, then to 12.5 mg, and finally to a
arget dose of 25 mg twice daily. The rapidity of up-titration
ould be slowed according to clinical need, as judged by the
nvestigator. Patients then entered a maintenance phase
uring which they were seen as outpatients every two
onths until the end of the study. Blood pressure measure-
ents were obtained every two weeks during up-titration
nd every two months during the maintenance phase. If
arranted by clinical circumstances, the dose of carvedilol or
lacebo could be reduced or temporarily discontinued, the
oses of all concomitant drugs could be adjusted, and the
nvestigator could implement any new treatments, except for
pen-label treatment with a beta-blocker.
The primary end point of COPERNICUS was all-cause
ortality. Prespecified secondary end points included the
ombined risk of death or hospitalization for HF, the
ombined risk of death or cardiovascular hospitalization, the
ombined risk of death or hospitalization for any reason,
nd the patient’s global assessment. Hospitalization for HF
as defined as an admission due to worsening HF (as the
rimary cause), due to another cause but associated with
orsening HF at the time of admission, or due to another
ause but complicated by worsening HF during its course.
ardiovascular hospitalization was defined as an admission
ue to or associated with atrial or ventricular tachyarrhy-
hmias, symptomatic bradycardia, heart block, myocardial
nfarction, or unstable angina pectoris, or an admission for
F. The cause of hospitalization was adjudicated by an end
oint committee, which had no knowledge of the patient’s
reatment assignment. Hospitalizations 24 h in duration,
ngoing at the time of randomization, or carried out only to
rovide housing for reasons of social service were not
ncluded as end points. The patient’s global assessment is a
ecord of how a patient feels compared with the start of the
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April 21, 2004:1423–9 The COPERNICUS Studytudy, according to a seven-category ordinal scale ranging
rom markedly improved to markedly worse.
The trial was monitored by an independent Data and
afety Monitoring Board, which recommended early termi-
ation of the study when it observed a marked effect of
arvedilol on survival (4). At the time of this early termi-
ation, the mean follow-up of patients in the study was 10.4
onths, and the maximum follow-up was 28.7 months.
tatistical analysis. Patients in the trial were retrospec-
ively grouped according to their pretreatment SBP into
0-mm Hg categories, starting from the lowest entry value
85 mm Hg) and collapsing patients with SBP 125 mm
g into a single group. Baseline characteristics among the
ve BP subgroups were compared using the Kruskal-Wallis
est for continuous variables and the chi-square test for
ategorical variables.
Cumulative survival curves for the risk of a major clinical
vent were constructed by the Kaplan-Meier method (using
time-to-first-event approach). Analyses of major outcome
ariables included all randomized patients, and all events
ere assigned to the patient’s randomized treatment group
according to the intention-to-treat principle). Patients who
nderwent heart transplantation or withdrew consent were
ensored from the date of these events. The relationships
etween pretreatment SBP, the effect of treatment, and the
isk of major clinical end points and other clinical events
ere examined using Cox proportional hazards regression
odels with pretreatment SBP included as a continuous
ariable. A treatment group by SBP interaction term was
ncluded in the model to assess the influence of SBP on the
elative magnitude of the treatment effect. These models
ere also used to estimate hazard ratios and 95% confidence
ntervals.
able 1. Baseline Characteristics of Study Population (n  2,289
85–95
o. of patients 132 (5.8%) 26
ge (yrs)* 61.2  12.4 60
ales (%) 82.6
uration of heart failure (yrs) 2.6  3.0 2
schemic etiology (%) 65.2
eft ventricular ejection fraction (%)* 18.3  4.6 18
eart rate (beats/min) 83.7  13.4 83
iastolic blood pressure (mm Hg)* 62.3  6.7 67
erum sodium (mmol/l)* 135.9  2.8 136
erum creatinine (mol/l)* 142.3  40.0 137
ody mass index (kg/m2)* 24.2  4.7 26
emoglobin (g/dl)* 13.3  1.8 13
oncomitant medications (%) 78.8
Digitalis* 98.5
Diuretics 95.5
ACE inhibitor/ATII 31.1
Spironolactone* 21.2
Amiodarone
Significant differences among SBP subgroups (p  0.05). Continuous data are expr
ACE  angiotensin-converting enzyme; ATII  angiotensin II antagonist; SBPThe effect of carvedilol on the patient’s global assessment tfter six months of maintenance therapy was evaluated using
he Wilcoxon rank-sum test. The relationship between
retreatment SBP and the effect of carvedilol on this end
oint was assessed using a proportional odds model, which
onsidered SBP as a continuous variable and included a
reatment by SBP interaction term. Analyses were carried
ut for all patients with available data, both with and
ithout worst rank assignment for the occurrence of a
issing value due to death.
The relationship between pretreatment SBP and the
roportion of patients on the target dose of study drug
including the possibility of an interaction between pretreat-
ent BP and treatment) was tested using a logistic model in
hich pretreatment SBP was included as a continuous
ariable.
Changes in BP from baseline were analyzed across time
sing repeated measures analysis of covariance and an
nstructured covariance matrix for the repeated measures in
rder to test for a differential pattern of change in BP over
ime, according to pretreatment SBP. Differences between
reatment groups at individual visits were compared using
he Wilcoxon rank-sum test.
All reported p values are two-sided and nominal.
ESULTS
f the 2,289 patients who were enrolled into the trial, the
retreatment SBPs were 85 to 95 mm Hg in 132 patients
5.8%), 96 to 105 mm Hg in 264 patients (11.5%), 106 to
15 mm Hg in 468 patients (20.4%), 116 to 125 mm Hg in
72 patients (20.6%), and 125 mm Hg in 953 patients
41.6%).
haracterization of BP subgroups. The baseline charac-
Pretreatment SBP (mm Hg)
5 106–115 116–125 >125
5%) 468 (20.4%) 472 (20.6%) 953 (41.6%)
11.8 63.5  12.2 62.6  11.6 64.5  10.6
82.5 80.3 77.9
2.8 2.6  2.8 2.8  3.4 2.7  3.1
64.1 66.1 70.1
4.1 19.6  4.4 20.0  3.8 20.5  3.6
12.8 82.6  12.4 83.3  12.2 82.5  12.3
8.0 71.6  7.6 76.4  7.8 83.1  9.9
3.5 136.8  2.7 137.0  2.6 137.2  2.5
40.8 134.5  38.5 130.6  33.9 133.0  34.8
5.1 26.4  4.9 27.1  4.7 27.6  4.5
2.0 13.9  1.7 14.0  1.7 13.9  1.7
66.9 67.0 61.3
99.4 98.7 99.0
97.9 96.2 97.7
21.6 19.7 15.0
16.0 18.4 17.6
as the mean value  SD.
tolic blood pressure.)
96–10
4 (11.
.9 
78.8
.5 
65.2
.5 
.2 
.8 
.4 
.1 
.2 
.8 
74.2
100.0
97.0
25.4
16.3
essed
 syseristics of patients grouped according to their pretreatment
S
S
l
t
s
d
m
1
t
d
c
f
I
w
t
c
t
c
t
f
a
f
(
w
g
m
c
c
g
A
o
a
v
I
m
r
d
c
(
t
t
m
a
t
p
o
p
p
e
i
I
A
t
m
o
b
u
g
s
t
(
r
t
r
c
(
d
c
r
w
i
f
t
p
d
H
F
(
d
c
c
1426 Rouleau et al. JACC Vol. 43, No. 8, 2004
The COPERNICUS Study April 21, 2004:1423–9BP are shown in Table 1. The lower the pretreatment
BP, the more advanced HF, as reflected by lower values for
eft ventricular ejection fraction, serum sodium concentra-
ion, hemoglobin, and body mass index, higher values of
erum creatinine, and a greater prevalence of the use of
igitalis and spironolactone.
The lower the pretreatment SBP, the higher the risk of a
ajor clinical event, irrespective of treatment (Figs. 1A and
B). For each 10-mm Hg decrease in the pretreatment SBP,
he risk of death increased by 18%, the combined risk of
eath or hospitalization for HF increased by 11%, and the
ombined risk of death or hospitalization for any reason or
or a cardiovascular reason increased by 9% (all p  0.001).
nfluence of SBP on effects of carvedilol. In the trial as a
hole and within each BP subgroup, patients randomized
o placebo or carvedilol were similar in their baseline
haracteristics (data not shown). Overall, carvedilol reduced
he risk of death by 35%, the combined risk of death or
ardiovascular hospitalization by 27%, death or hospitaliza-
ion for worsening HF by 31%, and death or hospitalization
or any reason by 24% (all p  0.001). The relative benefit,
s assessed by the Cox model hazard ratio, did not vary as a
unction of the pretreatment SBP (all interaction: p 0.10)
Fig. 2). However, because patients with the lowest SBP
ere at the highest risk of an event, they experienced the
igure 1. Kaplan-Meier survival curves of the time to all-cause mortality
A) and time to death or hospitalization for any reason (B) in subgroups
efined by pretreatment systolic blood pressure (both treatment groups
ombined). The lower the blood pressure, the higher the risk of a major
linical event (both p  0.0001).reatest absolute benefit from treatment with carvedilol. nMore patients considered themselves moderately or
arkedly improved (49.6% vs. 40.0%) and fewer patients
onsidered themselves moderately or markedly worse in the
arvedilol group (1.6% vs. 4.2%) compared with the placebo
roup after six months of maintenance therapy (p  0.001).
difference in favor of carvedilol was observed irrespective
f the pretreatment SBP (interaction: p  0.21 ) (Figs. 3A
nd 3B) and continued to be observed even when missing
alues due to death were assigned the worst rank.
nfluence of carvedilol on SBP. Overall, SBP declined
ore in patients treated with carvedilol than in those who
eceived placebo. At the final up-titration visit, SBP was
ecreased from baseline by a mean of 4.6 mm Hg in the
arvedilol group and by 2.4 mm Hg in the placebo group
p  0.001). This 2-mm Hg mean difference between the
wo groups persisted for approximately four months, but
hen dissipated and was no longer apparent after eight
onths (Fig. 4). The results were similar whether the
nalyses focused on all patients with data available at any
ime point or on all patients with complete data for all time
oints.
Pretreatment SBP values were a significant determinant
f the effects of carvedilol on BP across time (interaction:
 0.001). Most importantly, among patients with a
retreatment SBP of 85 to 95 mm Hg, there was no
vidence of any initial decline, and there may even be an
ncrease in SBP relative to placebo (Fig. 4).
nfluence of SBP on safety and tolerability of carvedilol.
fter initiation of treatment, most patients were successfully
itrated to and maintained on target doses of the study
edication. Excluding patients who did not have the
pportunity for full up-titration (either because they died or
ecause the study was terminated while they were being
p-titrated), 78% and 65% of the placebo and carvedilol
roups, respectively, were receiving the target dose of the
tudy drug at four months. The proportion of patients at the
arget dose increased as the pretreatment SBP increased
p  0.001), with no influence of treatment on this
elationship (interaction: p  0.66) (Fig. 5A). Fewer pa-
ients in the carvedilol group than in the placebo group
equired permanent discontinuation of the study drug be-
ause of adverse effects or for reasons other than death
12.6% vs. 15.9%, p  0.05). The frequency of permanent
rug withdrawal increased as the pretreatment SBP de-
reased (p  0.001), with no influence of treatment on this
elationship (interaction: p  0.25) (Fig. 5B).
The frequency of adverse events commonly associated
ith adrenergic blockade in the five BP subgroups is shown
n Table 2. The lower the pretreatment SBP, the higher the
requency of dizziness, hypotension, and HF events in both
reatment groups. More carvedilol-treated than placebo
atients reported dizziness, hypotension, syncope, and bra-
ycardia, whereas fewer carvedilol-treated patients reported
F, to a similar extent in each BP subgroup.
The pretreatment SBP was also an important determi-ant of the risk of a serious adverse event, with the risk of
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April 21, 2004:1423–9 The COPERNICUS Studyuch an event increasing as the pretreatment BP decreased
p  0.001). Nevertheless, patients treated with carvedilol
ere less likely to experience a serious adverse event during
he trial than patients who received placebo (39.0% vs.
5.5%, p  0.002). The benefit associated with carvedilol
reatment increased as the pretreatment SBP decreased
interaction: p  0.03) (Fig. 6).
ISCUSSION
ystolic BP is the most common physiologic measurement
erformed in patients with CHF and is frequently used by
linicians to determine the eligibility of patients for, the
herapeutic response to, and the tolerability of specific
reatments. Patients with an elevated BP are often regarded
s ideal candidates for treatment with ACE inhibitors and
eta-blockers, whereas both classes of drugs are commonly
voided in patients with a low SBP because of concerns
bout their hypotensive effects. The validity of using SBP as
guide to treatment has not been critically evaluated,
owever. Systolic BP does not appear to be a determinant of
he response to ACE inhibitors in large-scale trials (9), and
reliminary evidence suggests that it may also not influence
he response to beta-blockers in HF (3). However, data on
he importance of SBP in modulating the effects of both
CE inhibitors and beta-blockers are limited, as patients
ith a low SBP were not enrolled in most large-scale trials
igure 2. Hazard ratios and 95% confidence intervals for all-cause mortality, d
eath or any hospitalization in subgroups defined by pretreatment systolic blood
f carvedilol was consistent across all levels of pretreatment systolic blood preeath or hospitalization for heart failure, death or cardiovascular hospitalization, and
pressure. Hazard ratios1.0 indicate lower risk in the carvedilol group. The benefitith these drugs (2,3). iigure 3. Proportion of patients reporting themselves to be moderately or
arkedly improved (A) or moderately or markedly worse (B) after six months
f maintenance therapy, according to pretreatment systolic blood pressure and
reatment. The benefit of carvedilol on patient well-being was similar,
rrespective of pretreatment systolic blood pressure (interaction: p  0.21).
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The COPERNICUS Study April 21, 2004:1423–9The current analysis demonstrates that, in a trial enrolling
atients with a wide spectrum of values for SBP, long-term
reatment with carvedilol exerts favorable clinical effects in
atients with severe CHF, and this benefit is observed
egardless of the pretreatment BP. Carvedilol substantially
educed the risk of death and the combined risk of death or
ll-cause or cause-specific hospitalization, and the magni-
ude of these effects was similar in patients with low or
reserved SBP. The pretreatment SBP also did not influ-
nce the magnitude of symptomatic improvement produced
y the drug, as evaluated by the patient’s global assessment.
hese observations challenge the conventional belief that
atients with a low SBP respond poorly to adrenergic
lockade (10). In fact, because SBP is a major determinant
f risk, patients with the lowest SBP might be expected to
erive the greatest absolute benefit from treatment. In the
urrent trial, assuming a homogeneous relative reduction in
he risk of death with carvedilol by 35%, the number of
atients needed to treat with carvedilol for one year to save
ne life would be 20 in patients with SBP of125 mm Hg,
able 2. Frequency of Adverse Events Commonly Attributed to
Adverse Event Treatment Group
85–95
(n  132)
96–1
(n 
eart failure Placebo 58% 45%
Carvedilol 44% 40%
izziness Placebo 32% 27%
Carvedilol 39% 32%
ypotension Placebo 26% 20%
Carvedilol 27% 29%
yncope Placebo 6% 9%
Carvedilol 10% 7%
radycardia Placebo 5% 3%
Carvedilol 11% 10%
Numbers in the table represent the percentage of patients reporting the event.
igure 4. Mean change in systolic blood pressure (SBP) from baseline at
pecific visits in the placebo and carvedilol groups for all patients and for
atients with the lowest pretreatment systolic blood pressure (85 to 95 mm
g). *Significant treatment group difference (p  0.05).SBP  systolic blood pressure.ut only 10 in patients with SBP of 85 to 95 mm Hg, based
n the observed one-year placebo absolute mortality risks of
5.4% and 33.9%, respectively, in the two subgroups.
To achieve these benefits, physicians must be willing to
nitiate and maintain treatment with a beta-blocker in
atients with a low SBP, but many of them may be hesitant
o do so based on the fear that treatment will be poorly
olerated in this cohort. In the current analysis, the lower
he pretreatment SBP, the more likely that patients would
eport hypotension, dizziness, and worsening HF (Table 2).
urthermore, patients with the lowest SBP before the start
f treatment were most likely to be unable to achieve high
oses of the study drug and to require permanent with-
rawal of treatment. However, our analyses indicate that
igure 5. Proportion of patients at target dose of study drug at four months
A) or permanently withdrawn from the study drug (B), according to
retreatment systolic blood pressure and treatment. Pretreatment blood
ressure influenced the frequency of both occurrences (both p  0.001),
rrespective of pretreatment systolic blood pressure (interaction: p  0.24).
nergic Blockade*
Pretreatment SBP (mm Hg)
106–115
(n  468)
116–125
(n  472)
>125
(n  953)
All Patients
(n  2,289)
32% 34% 28% 34%
28% 26% 24% 28%
20% 13% 12% 17%
27% 27% 17% 24%
10% 6% 4% 9%
19% 17% 7% 15%
5% 7% 3% 5%
8% 8% 7% 8%
2% 4% 3% 3%
15% 11% 11% 12%Adre
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April 21, 2004:1423–9 The COPERNICUS Studyhese risks were related to the severity of the underlying
llness of these patients and not to the treatment they
eceived. Patients with a lower SBP were as likely to be
ntolerant of and require the withdrawal of placebo as they
ere of carvedilol. Moreover, patients treated with carve-
ilol were less likely to experience a serious adverse event
han those treated with placebo, and this difference in favor
f carvedilol was most apparent in patients with the lowest
BP (interaction: p  0.03). Consequently, the results of
he present analysis support concerns about the fragility of
atients with a low SBP, but suggest that this fragility is not
nhanced and may be reduced by treatment with carvedilol.
Our findings indicate that carvedilol was remarkably well
olerated in patients with the lowest SBP. Although BP
eclined with carvedilol in patients with higher pretreat-
ent values, there was little decrease or actually a small
ncrease in BP after therapy with carvedilol in patients with
he lowest SBP before treatment. As a result, in patients
ith SBP of 85 to 95 mm Hg, the frequency of hypotension
eported as an adverse event was not increased by treatment
ith carvedilol. Furthermore, despite the advanced severity
f disease in patients with the lowest pretreatment BP, the
isk of worsening HF was lower in the carvedilol group in
his subgroup than it was in subgroups with higher BPs.
ost of the episodes of hypotension and worsening HF that
ccurred in patients with the lowest SBP were related to the
nderlying disease (as reflected by the frequency of occur-
ence in the placebo group), with little incremental risk
elated to treatment with carvedilol. Hence, if physicians are
oncerned about prescribing beta-blockers because of fears
f hypotension and worsening HF, such concerns should
ot be magnified simply because the SBP is low before
reatment.
The current analysis suggests that the clinical importance
f a low SBP is primarily related to its ability to identify
atients with advanced disease, rather than to its ability to
dentify patients at risk of treatment with a beta-blocker.
he lower the pretreatment SBP, the more advanced HF, as
eflected by lower values of left ventricular ejection fraction
nd serum sodium concentration, higher values of serum
reatinine, and a greater prevalence of the use of digoxin and
pironolactone. Not surprisingly, the lower the pretreatment
igure 6. Proportion of patients experiencing a serious adverse event,
ccording to pretreatment systolic blood pressure and treatment. There was
decrease in the risk of an event with increasing systolic blood pressure in
oth treatment groups (p 0.001). The decrease associated with carvedilol
reatment increased significantly with decreasing systolic blood pressure
interaction: p  0.03).BP, the higher the risk of death and hospitalization,
rrespective of treatment. Previous studies have only infre-
uently identified SBP as a prognostic factor (11–14),
ossibly because BP declines when patients with HF are
reated with drugs that prolong life. Furthermore, earlier
eports also focused on patients with mild to moderate
ymptoms, and the prognostic importance of BP may
ncrease as HF advances.
The results of the COPERNICUS trial indicate that
atients with a low SBP benefit from and tolerate treatment
ith carvedilol to the same degree as patients with higher
Ps. In fact, by identifying patients at highest risk, the
retreatment BP can identify patients with the greatest need
or risk reduction with carvedilol.
eprint requests and correspondence: Dr. Jean L. Rouleau,
.P. 6128, Succursale Centre-ville, Montreal, Quebec, H3C 3J7,
anada. E-mail: jean.rouleau@umontreal.ca.
EFERENCES
1. Packer M, Bristow MR, Cohn JN, et al., for the U.S.Carvedilol Heart
Failure Study Group. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl J Med
1996;334:1349–55.
2. The CIBIS-II Investigators and Committees. The Cardiac Insuffi-
ciency BIsoprolol Study II (CIBIS-II). Lancet 1999;353:9–13.
3. The MERIT-HF Study Group. Effect of metoprolol CR/XL in
chronic heart failure: Metoprolol CR/XL Randomized Intervention
Trial in congestive Heart Failure (MERIT-HF). Lancet 1999;353:
2001–7.
4. Packer M, Coats AJS, Fowler MB, et al., for the Carvedilol Prospec-
tive Randomized Cumulative Survival Study Group. Effect of carve-
dilol on survival in severe chronic heart failure. N Engl J Med
2001;344:1651–8.
5. Gaffney TE, Braunwald E. Importance of adrenergic nervous system
in the support of circulatory function in patients with congestive heart
failure. Am J Med 1963;34:320–4.
6. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening
heart failure early after initiation of beta-blocker therapy for chronic
heart failure preclude long-term treatment (abstr)? Circulation
1995;92 Suppl I:I395.
7. Waagstein F, Caidahl K, Wallentin I, Bergh C, Hjalmarson A.
Long-term beta-blockade in dilated cardiomyopathy: effects of short-
and long-term metoprolol treatment followed by withdrawal and
re-administration of metoprolol. Circulation 1989;80:551–63.
8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the
morbidity of patients with severe chronic heart failure: results of the
Carvedilol Prospective Randomized Cumulative Survival (COPER-
NICUS) study. Circulation 2002;106:2194–9.
9. Garg R, Yusuf S. Overview of randomized trials of angiotensin-
converting enzyme inhibitors on mortality and morbidity in patients
with heart failure. JAMA 1995;273:1450–6.
0. Physician’s Desk Reference. Prescribing Information. Tenormin I.V.
injection (atenolol). Thompson, 2004.
1. Canesin MF, Giorgi D, de Oliveira MT, et al. Ambulatory blood
pressure monitoring of patients with heart failure: a new prognosis
marker. Arq Bras Cardiol 2002;78:83–9.
2. Franciosa JA, Wilen M, Ziesche S, et al. Survival in men with severe
chronic left ventricular failure due to either coronary artery disease or
idiopathic dilated cardiomyopathy. Am J Cardiol 1983;51:831–6.
3. Cleland JGF, Dargie HJ, Ford I. Mortality in heart failure: clinical
variables of prognostic value. Br Heart J 1987;58:572–82.
4. Ghali JK, Kadakia S, Bhatti A, et al. Survival of heart failure patients
with preserved versus impaired systolic function: the prognostic im-
plication of blood pressure. Am Heart J 1992;123:993–7.
